Note that some links may require subscriptions.
A second student survivor of the Parkland school shooting died by suicide, less than a week after the first. (Washington Post)
What would ‘Medicare for All’ really mean for employees, industry and the cost of care? The New York Times explains.
No approval forthcoming for Sanofi’s and Lexicon Pharmaceuticals’ SGLT-1/2 inhibitor sotagliflozin for type 1 diabetes; the FDA sends the firms a Complete Response Letter, details of which weren’t made public. In January, an FDA advisory committee had split on whether the drug should be approved.
An infant boy in Italy died after his parents attempted to perform a circumcision on him at home. (AP)
A small study is slated to test the controversial “abortion reversal” regimen in a placebo-controlled trial of women seeking abortions. (NPR)
One expert shares the story of a patient so afraid of the stigma associated with lung cancer, she took her diagnosis to her grave. (KevinMD)
Manufacturer Eli Lilly said net revenues for its fast-acting insulin Humalog fell 8% since 2014. (STAT+)
That chemical-plant fire in suburban Houston just gets worse, spewing gunk into local waterways as well as the air. (CNN)
More fellowship programs are offering advanced training for doctors who want to learn more about treating patients with addiction. (NBC News)
The highly touted CBD trend is smoking hot, so how can farmers keep up with all that demand for industrial hemp? (CNBC)
Certain California-grown avocados are recalled in six states after concerns about contamination with Listeria. (USA Today)
Morning Break is a daily guide to what’s new and interesting on the Web for healthcare professionals, powered by the MedPage Today community. Got a tip? Send it to us: [email protected]